Compound class:
Synthetic organic
Comment: BMS-986121 is a positive allosteric modulator (PAM) of the μ opioid receptor [3]. It is one of the compounds claimed in patent WO2014107344 [2]. BMS-986121 is built on a chemical scaffold representing a new chemotype for μ receptor PAMs [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Bisignano P, Burford NT, Shang Y, Marlow B, Livingston KE, Fenton AM, Rockwell K, Budenholzer L, Traynor JR, Gerritz SW et al.. (2015)
Ligand-Based Discovery of a New Scaffold for Allosteric Modulation of the μ-Opioid Receptor. J Chem Inf Model, 55 (9): 1836-43. [PMID:26347990] |
2. Burford N, Alt A. (2014)
Positive allosteric modulators and silent allosteric modulators of the opioid receptor. Patent number: WO2014107344. Assignee: Bristol-Myers Squibb Company. Priority date: 04/01/2013. Publication date: 10/07/2014. |
3. Burford NT, Clark MJ, Wehrman TS, Gerritz SW, Banks M, O'Connell J, Traynor JR, Alt A. (2013)
Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor. Proc Natl Acad Sci USA, 110 (26): 10830-5. [PMID:23754417] |